Simplex Trading’s Cardiol Therapeutics CRDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-32,197
Closed -$33K 9228
2025
Q4
$30.7K Buy
32,197
+15,742
+96% +$16.5K ﹤0.01% 6090
2025
Q3
$17K Buy
+16,455
New +$20K ﹤0.01% 7450
2023
Q4
Sell
-1,054
Closed -$896 8914
2023
Q3
$0 Buy
1,054
+215
+26% +$205 ﹤0.01% 8805
2023
Q2
$0 Buy
+839
New +$554 ﹤0.01% 9104
2022
Q3
Sell
-8,365
Closed -$10.2K 10023
2022
Q2
$11K Sell
8,365
-16,210
-66% -$23.1K ﹤0.01% 8186
2022
Q1
$37K Buy
+24,575
New +$40.5K ﹤0.01% 7525

Other funds holding CRDL

Simplex Trading's CRDL Position: Q1 2026 in Review

Simplex Trading sold out of Cardiol Therapeutics (CRDL) in Q1 2026, closing a stake of 32,197 shares — an estimated $33K sold.

Simplex Trading first reported a position in CRDL in Q1 2022 and held it in 6 quarters. The position peaked at $37K in Q1 2022. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Simplex Trading reported no remaining Cardiol Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 32,197 Cardiol Therapeutics shares in Q1 2026, an estimated $33K.
  • Simplex Trading first reported a position in Cardiol Therapeutics in Q1 2022 and held it in 6 quarters.
  • Simplex Trading's Cardiol Therapeutics position peaked at $37K in Q1 2022.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.